Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering
03 janv. 2022 17h07 HE
|
Interpace Biosciences, Inc.
Proceeds to be used to fund the organic growth and prospective product line acquisitions PARSIPPANY, NJ, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”)...
Interpace Pharma Solutions Announces New Capability in Spatial Biology/Precision Oncology Services
17 mai 2021 08h00 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, May 17, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that it will...
Interpace Biosciences to Explore Strategic Alternatives for Maximizing Shareholder Value
22 avr. 2021 08h00 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, April 22, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today issued the following statement. Interpace continues to make...
Interpace Biosciences’ Audit Committee Investigation Finds Complaints Unsubstantiated
14 oct. 2020 06h30 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (Nasdaq: IDXG) announced today that the Audit Committee of the Board of Directors has...
Interpace Biosciences to Host Conference Call and Webcast to Discuss First Quarter, 2020 Financial Results on Thursday June 25, 2020
24 juin 2020 16h20 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, June 24, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences (IDXG) announced today that it will report its first quarter, 2020 financial results on Thursday, June 25, 2020 at 4:30 p.m....
Interpace Biosciences Announces Contract with Lab Benefits Management Firm
27 avr. 2020 06h55 HE
|
Interpace Biosciences, Inc.
In-Network Access for More Than 3 Million Members Parsippany, NJ, April 27, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences (NASDAQ: IDXG) announced today that its subsidiary, Interpace...
Interpace Biosciences Announces Acceptance of first paper Demonstrating Clinical Performance of ThyGeNEXT with ThyraMIR
02 mars 2020 06h55 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, March 02, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced acceptance of the first manuscript reporting the clinical performance of the company’s...
Global Medical Vaccum Market is Expected to Reach USD 1.88 Billion by 2026 : Fior Markets
28 août 2019 09h34 HE
|
Fior Markets
New Jersey, NJ, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Growing geriatric population world over, technological progress in the vacuum systems, increasing number of diagnostic imaging procedures,...
Interpace Diagnostics to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results on Tuesday, August 13, 2019
06 août 2019 16h05 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it will report its second quarter 2019 financial results on Tuesday, August...
Growth in Neuroprotective Agents Market Projected to 2022
18 juin 2018 06h00 HE
|
BCC Research
WELLESLEY, Mass., June 18, 2018 (GLOBE NEWSWIRE) -- Longer life spans, the increasing prevalence of neurological disorders (particularly neurodegenerative diseases), stroke and traumatic central...